These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35517470)

  • 1. Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide.
    Zhang A; Lin Y; Nong S; Zhao W; Dong M
    RSC Adv; 2020 Jun; 10(42):25013-25021. PubMed ID: 35517470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
    Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
    Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies.
    Li P; Zhang J; Jia Y; Zhang Y
    Life Sci; 2020 Aug; 254():117752. PubMed ID: 32387412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.
    Gong N; Ma AN; Zhang LJ; Luo XS; Zhang YH; Xu M; Wang YX
    Br J Pharmacol; 2011 May; 163(2):399-412. PubMed ID: 21244372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.
    Sun L; Huang X; Han J; Cai X; Dai Y; Chu Y; Wang C; Huang W; Qian H
    Biochem Pharmacol; 2016 Jun; 110-111():80-91. PubMed ID: 27155328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
    Kim TH; Park CW; Kim HY; Chi MH; Lee SK; Song YM; Jiang HH; Lim SM; Youn YS; Lee KC
    Biol Pharm Bull; 2012; 35(7):1076-83. PubMed ID: 22791155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mono-PEGylates of exenatide in branched and dimeric structures can improve in vivo stability and hypoglycemic bioactivity.
    Thi Nguyen NT; Jung S; Lee SH; Bae ON; Lee EK
    J Biotechnol; 2019 Dec; 306():89-96. PubMed ID: 31580912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
    Xu S; Wang F; Li H; Wang Y; Fang D
    Bioengineered; 2022 Mar; 13(3):4621-4633. PubMed ID: 34696658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.
    Niu X; Nong S; Zhang X; Li X; Wang C; Li W; Zhou T
    RSC Adv; 2020 Jan; 10(8):4725-4732. PubMed ID: 35495226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.
    Kim I; Kim TH; Ma K; Lee ES; Kim D; Oh KT; Lee DH; Lee KC; Youn YS
    Bioconjug Chem; 2010 Aug; 21(8):1513-9. PubMed ID: 20715855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Separation of mono- and di-PEGylate of exenatide and resolution of positional isomers of mono-PEGylates by preparative ion exchange chromatography.
    Nguyen NT; Lee JS; Yun S; Lee EK
    J Chromatogr A; 2016 Jul; 1457():88-96. PubMed ID: 27363735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.
    Li C; Cai X; Dai Y; Liu C; Bi X; Zhou J; Li Q; Sun L; Huang W; Hou Z; Qian H
    Bioorg Med Chem; 2019 Oct; 27(20):115070. PubMed ID: 31471103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.
    Tang D; Tian H; Wu J; Cheng J; Luo C; Sai W; Song X; Gao X; Yao W
    J Pharmacol Sci; 2018 Sep; 138(1):23-30. PubMed ID: 30309736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
    Levy OE; Jodka CM; Ren SS; Mamedova L; Sharma A; Samant M; D'Souza LJ; Soares CJ; Yuskin DR; Jin LJ; Parkes DG; Tatarkiewicz K; Ghosh SS
    PLoS One; 2014; 9(2):e87704. PubMed ID: 24503632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
    Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
    Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.